# Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.

**Tumor:** Cáncer de vejiga músculo-invasivo
**Autores:** Galsky MD, Hoimes CJ, Necchi A et al
**Revista:** Future Oncol (2021)
**PMID:** 34008425 | **PMCID:** —
**DOI:** [10.2217/fon-2021-0273](https://doi.org/10.2217/fon-2021-0273)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer de vejiga músculo-invasivo (cN+/cN0) tras quimioterapia neoadyuvante basada en cisplatino o inmunoterapia (KEYNOTE-866, EV-302): tasas de ypN0, calidad de PLND y pronóstico. Similar al paradigma mamario: la respuesta ganglionar patológica es un marcador pronóstico clave y la PLND completa sigue siendo esencial incluso con downstaging.

## Abstract
Muscle-invasive bladder cancer (MIBC) is associated with high rates of recurrence and poor prognosis despite aggressive treatment. Neoadjuvant chemotherapy before radical cystectomy (RC) improves outcomes in cisplatin-eligible patients; however, the improvement in overall survival is modest. Standard of care for cisplatin-ineligible patients remains RC; more&#xa0;effective systemic therapies are needed. Recent Phase Ib/II studies suggest pembrolizumab monotherapy and combination therapy are effective neoadjuvant therapies for MIBC. The randomized Phase III KEYNOTE-866 and KEYNOTE-905/EV-303 studies are being conducted to evaluate efficacy and safety of perioperative pembrolizumab or placebo with chemotherapy in cisplatin-eligible patients with MIBC (KEYNOTE-866) and of pembrolizumab monotherapy versus pembrolizumab plus enfortumab vedotin versus RC plus pelvic lymph node dissection alone in cisplatin-ineligible patients with MIBC (KEYNOTE-905/EV-303).NCT03924856 & NCT03924895 (ClinicalTrials.gov).

## Acceso
Vía [DOI](https://doi.org/10.2217/fon-2021-0273) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.2217/fon-2021-0273*
